Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Mid-Stabilisation Period Announcement

20 Mar 2017 07:00

RNS Number : 8801Z
Arix Bioscience Plc
20 March 2017
 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTIONS WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

20th March 2017

Mid-Stabilisation Period Announcement

Arix Bioscience Plc (the "Company")

Further to the pre-stabilisation period announcement dated 17th February 2017, Jefferies International Limited (contact: Luca Erpici +44 (0)20 7029 8415; Lee Morton +44 (0)20 7029 8753) hereby gives notice that the Stabilisation manager named below undertook stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in relation to the offer of the following securities, as set out below:

 

Issuer:

Arix Bioscience Plc

Securities:

Ordinary Shares (ISIN: GB00BD045071)

Offering Size:

48,309,179 Ordinary shares excluding the over-allotment option

Offer Price:

207p per ordinary share

Market:

London Stock Exchange, Over-The-Counter (OTC) and other order book venues e.g. Turquoise, BATS and Chi-X

Ticker:

ARIX

Stabilising Manager:

Jefferies International Limited

 

Stabilisation Transactions:

Date of Execution

Time of Execution (GMT)

Quantity

Price

Execution Venue

13/03/2017

11:24:39

25,000

207

London Stock Exchange

13/03/2017

12:12:30

10,000

207

London Stock Exchange

16/03/2017

08:08:43

50

207

London Stock Exchange

16/03/2017

08:08:43

25,000

207

London Stock Exchange

16/03/2017

08:18:36

600

207

London Stock Exchange

16/03/2017

08:18:36

600

207

London Stock Exchange

16/03/2017

08:18:36

25,000

207

London Stock Exchange

16/03/2017

08:46:40

600

207

London Stock Exchange

16/03/2017

08:46:40

600

207

London Stock Exchange

16/03/2017

08:46:40

600

207

London Stock Exchange

16/03/2017

08:46:40

600

207

Chi-X

16/03/2017

08:46:40

600

207

Chi-X

16/03/2017

08:47:33

779

206

London Stock Exchange

16/03/2017

08:54:17

440

207

Turquoise

16/03/2017

08:54:17

160

207

BATS

16/03/2017

08:58:20

280

207

BATS

16/03/2017

08:58:20

320

207

Turquoise

16/03/2017

09:01:52

120

207

Turquoise

16/03/2017

09:01:52

440

207

BATS

16/03/2017

09:01:52

40

207

London Stock Exchange

16/03/2017

09:15:57

440

207

Turquoise

16/03/2017

09:15:57

160

207

BATS

16/03/2017

09:17:58

280

207

BATS

16/03/2017

09:17:58

320

207

London Stock Exchange

16/03/2017

09:31:38

600

207

London Stock Exchange

16/03/2017

09:34:25

600

207

London Stock Exchange

16/03/2017

09:36:41

600

207

London Stock Exchange

16/03/2017

09:51:24

600

207

London Stock Exchange

16/03/2017

09:53:52

600

207

London Stock Exchange

16/03/2017

09:55:34

600

206.5

London Stock Exchange

16/03/2017

10:08:50

380

207

London Stock Exchange

16/03/2017

10:08:50

220

207

London Stock Exchange

16/03/2017

10:19:30

600

207

London Stock Exchange

16/03/2017

10:26:13

600

207

London Stock Exchange

16/03/2017

10:28:33

538

207

London Stock Exchange

16/03/2017

10:28:33

62

207

London Stock Exchange

16/03/2017

10:41:06

600

207

London Stock Exchange

16/03/2017

10:45:25

600

207

London Stock Exchange

16/03/2017

10:57:41

538

207

London Stock Exchange

16/03/2017

11:32:46

600

207

London Stock Exchange

16/03/2017

11:32:46

600

207

London Stock Exchange

16/03/2017

11:32:46

600

207

London Stock Exchange

16/03/2017

11:33:52

600

207

London Stock Exchange

16/03/2017

11:37:41

600

207

London Stock Exchange

16/03/2017

11:51:23

600

207

London Stock Exchange

16/03/2017

11:54:13

600

207

London Stock Exchange

16/03/2017

12:10:02

600

207

London Stock Exchange

16/03/2017

12:20:09

600

207

London Stock Exchange

16/03/2017

12:27:10

600

207

London Stock Exchange

16/03/2017

12:37:31

600

207

London Stock Exchange

16/03/2017

12:45:17

7

207

London Stock Exchange

16/03/2017

12:45:17

593

207

London Stock Exchange

16/03/2017

12:55:01

7

207

London Stock Exchange

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:46

462

207

Chi-X

16/03/2017

15:17:46

600

207

Chi-X

16/03/2017

15:17:46

600

207

Chi-X

16/03/2017

15:17:46

600

207

Chi-X

17/03/2017

09:08:03

2325

207

London Stock Exchange

 

Disclaimer:

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

This announcement and copies of this announcement are not being made and may not be distributed, published, or sent, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, South Africa or Japan or to any persons in any of those jurisdictions or any other jurisdictions where to do so would be unlawful or would require registration or other measures. The release, publication or distribution of this announcement in other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions.

The Offer and the distribution of this announcement and other information in connection with the listing and Offer in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not and does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase any securities in the United States, Australia, Canada, Japan, South Africa or any other jurisdiction where such an offer would be unlawful.

The Securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable laws of any state or other jurisdiction of the United States. The securities are being offered and sold outside the United States in offshore transactions as defined in, and in compliance with, Regulation S under the US Securities Act or within the United States only to "Qualified Institutional Buyers" ("QIBS") as defined in Rule 144A under the US Securities Act ("Rule 144"), who are also, in each case, "Qualified Purchasers" ("QPs"), as defined in section 2(a)(51) of the Investment Act of 1940, as amended (the "Investment Company Act"), or pursuant to another exemption form, or in a transaction not subject to, the registration requirements of the US Securities Act. Any forwarding, distribution or reproduction of this announcement, the publication in which it is contained and any copy of it in whole or in part is unauthorised. Failure to comply with this notice may result in a violation of the US Securities Act or the applicable laws or other jurisdictions. This announcement does not contain or constitute an offer to buy or subscribe for, the securities referred to herein to any person in any jurisdiction where it is unlawful to do so. The Company does not intend to register any part of the Offer in the United States and there will be no public offering of securities in the United States.

The Securities have not been and will not be registered under the applicable securities laws of Canada, Japan, South Africa or Australia and may not be offered or sold in Canada, Japan, South Africa or Australia except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the applicable securities laws. There will be no public offering of securities in Canada, Japan, South Africa or Australia.

This announcement is only addressed to, and directed at, persons in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive ("Qualified Investors"). For the purposes of this provision, the expression "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each member state of the European Economic Area which has implemented the Prospectus Directive. In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments who fall within the definition of "investment professional" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) who are high net worth companies, unincorporated associations and partnerships and trustees of high value trusts or other persons to whom it may otherwise lawfully be communicated falling within Article 49(2)(a)-(d) of the Order, (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this announcement relates is available only to and will only be engaged in with such persons. This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons; and (ii) in any member state of the European Economic Area other than the United Kingdom, by persons who are not Qualified Investors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STADXGDXRSBBGRC
Date   Source Headline
21st Feb 20187:00 amRNSArix Bioscience and Ipsen sign strategic agreement
19th Feb 20187:00 amRNSArix signs strategic agreement with Fosun
4th Jan 20182:00 pmRNSCEO Letter to Shareholders
3rd Jan 20189:46 amRNSVoting Rights and Capital: Month End Disclosure
22nd Dec 20177:00 amRNSIssue of Ordinary Shares, TVR, PDMR Shareholding
21st Dec 20177:00 amRNSArix co-leads $30m financing for Aura Biosciences
4th Dec 20177:00 amRNSArix Bioscience leads $30m financing for Atox Bio
10th Nov 20179:00 amRNSSir John Banham retires from Board of Directors
1st Nov 20177:00 amRNSArix to present at two IR conferences
18th Oct 20171:31 pmRNSArix notes Harpoon AbbVie IO collaboration
17th Oct 20177:10 amRNSDirector Declaration
17th Oct 20177:00 amRNSGiles Kerr Appointed to Board of Directors
10th Oct 20177:00 amRNSArix Bioscience notes positive data from Amplyx
26th Sep 20177:00 amRNSArix participates in $80 million Autolus financing
18th Sep 20177:20 amRNSClinical progress from Autolus
18th Sep 20177:00 amRNSCapital Markets Meeting Today
14th Sep 20177:00 amRNSArix Bioscience Capital Markets Meeting
8th Sep 20174:27 pmRNSArix to present at Rodman & Renshaw conference
7th Sep 20172:00 pmRNSArix notes positive Verona data in COPD
4th Sep 20177:05 amRNSArix Bioscience notes Artios CSO Appointment
2nd Aug 20177:00 amRNSArix participates in $67m financing for Amplyx
31st Jul 20177:00 amRNSReport for the Six Months Ended 30 June 2017
27th Jul 20177:00 amRNSArix Bioscience: $29M Series A for PreciThera
21st Jul 20173:17 pmRNSMeghan FitzGerald appointed to Board of Directors
17th Jul 20177:00 amRNSNotice of Results
10th Jul 20177:00 amRNSArix Bioscience plc Appoints General Counsel
28th Jun 20177:00 amRNSArix Bioscience leads $45M financing round
27th Jun 201712:00 pmRNSArix Bioscience in $20M Mitoconix Bio fundraise
12th Jun 20177:01 amRNSArix notes Artios collaboration
5th Jun 20173:45 pmRNSResult of AGM
5th Jun 20177:00 amRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSArix to present at Jefferies Healthcare Conference
30th May 20177:00 amRNSDirector/PDMR Shareholding
30th May 20177:00 amRNSAppointment of Jefferies and Stifel as brokers
26th May 20174:35 pmRNSPrice Monitoring Extension
25th May 20177:00 amRNSArix Bioscience Leads Harpoon Therapeutics Round
19th May 20177:00 amRNSArix leads $65m Series B investment for Iterum
9th May 20177:00 amRNSDirector share purchases
28th Apr 201712:04 pmRNSArix Notes Verona's NASDAQ Listing
28th Apr 20178:00 amRNSAnnual Financial Report
18th Apr 201712:00 pmRNSGroup business Verona receives IND for RPL554
31st Mar 20177:00 amRNSBoard Committee Changes
22nd Mar 20172:52 pmRNSHolding(s) in Company
20th Mar 20177:05 amRNSArix Bioscience, LDC, Leeds University Agreement
20th Mar 20177:02 amRNSPartial Exercise of Over-Allotment Option
20th Mar 20177:01 amRNSEnd of Stabilisation Notice
20th Mar 20177:00 amRNSMid-Stabilisation Period Announcement
10th Mar 20174:30 pmRNSMid-Stabilisation Period Announcement
10th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20177:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.